vs
奥尼兰姆制药（ALNY）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
奥尼兰姆制药的季度营收约是Reddit, Inc.的1.8倍（$1.2B vs $663.0M），Reddit, Inc.净利率更高（30.8% vs 17.6%，领先13.1%），奥尼兰姆制药同比增速更快（96.4% vs 69.0%），过去两年Reddit, Inc.的营收复合增速更高（53.6% vs 33.0%）
奥尼兰姆制药是美国生物制药企业，2002年成立，总部位于马萨诸塞州剑桥市，专注于研发及商业化针对基因明确疾病的RNA干扰（RNAi）疗法，2016年入选福布斯「100家最具创新力成长企业」榜单。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
ALNY vs RDDT — 直观对比
营收规模更大
ALNY
是对方的1.8倍
$663.0M
营收增速更快
ALNY
高出27.4%
69.0%
净利率更高
RDDT
高出13.1%
17.6%
两年增速更快
RDDT
近两年复合增速
33.0%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $663.0M |
| 净利润 | $206.0M | $204.0M |
| 毛利率 | 82.2% | 100.0% |
| 营业利润率 | 23.0% | 0.0% |
| 净利率 | 17.6% | 30.8% |
| 营收同比 | 96.4% | 69.0% |
| 净利润同比 | — | 680.0% |
| 每股收益（稀释后） | $1.51 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALNYRDDT
| Q1 26 | $1.2B | $663.0M | ||
| Q4 25 | $1.1B | $725.6M | ||
| Q3 25 | $1.2B | $584.9M | ||
| Q2 25 | $773.7M | $499.6M | ||
| Q1 25 | $594.2M | $392.4M | ||
| Q4 24 | $593.2M | $427.7M | ||
| Q3 24 | $500.9M | $348.4M | ||
| Q2 24 | $659.8M | $281.2M |
净利润ALNYRDDT
| Q1 26 | $206.0M | $204.0M | ||
| Q4 25 | $186.4M | $251.6M | ||
| Q3 25 | $251.1M | $162.7M | ||
| Q2 25 | $-66.3M | $89.3M | ||
| Q1 25 | $-57.5M | $26.2M | ||
| Q4 24 | $-83.8M | $71.0M | ||
| Q3 24 | $-111.6M | $29.9M | ||
| Q2 24 | $-16.9M | $-10.1M |
毛利率ALNYRDDT
| Q1 26 | 82.2% | 100.0% | ||
| Q4 25 | 75.6% | 91.9% | ||
| Q3 25 | 84.2% | 91.0% | ||
| Q2 25 | 81.6% | 90.8% | ||
| Q1 25 | 88.2% | 90.5% | ||
| Q4 24 | 82.7% | 92.6% | ||
| Q3 24 | 83.6% | 90.1% | ||
| Q2 24 | 89.8% | 89.5% |
营业利润率ALNYRDDT
| Q1 26 | 23.0% | 0.0% | ||
| Q4 25 | 12.0% | 31.9% | ||
| Q3 25 | 29.5% | 23.7% | ||
| Q2 25 | -2.1% | 13.6% | ||
| Q1 25 | 3.0% | 1.0% | ||
| Q4 24 | -17.7% | 12.4% | ||
| Q3 24 | -15.4% | 2.0% | ||
| Q2 24 | 7.4% | -11.0% |
净利率ALNYRDDT
| Q1 26 | 17.6% | 30.8% | ||
| Q4 25 | 17.0% | 34.7% | ||
| Q3 25 | 20.1% | 27.8% | ||
| Q2 25 | -8.6% | 17.9% | ||
| Q1 25 | -9.7% | 6.7% | ||
| Q4 24 | -14.1% | 16.6% | ||
| Q3 24 | -22.3% | 8.6% | ||
| Q2 24 | -2.6% | -3.6% |
每股收益（稀释后）ALNYRDDT
| Q1 26 | $1.51 | $1.01 | ||
| Q4 25 | $1.44 | $1.24 | ||
| Q3 25 | $1.84 | $0.80 | ||
| Q2 25 | $-0.51 | $0.45 | ||
| Q1 25 | $-0.44 | $0.13 | ||
| Q4 24 | $-0.66 | $4.76 | ||
| Q3 24 | $-0.87 | $0.16 | ||
| Q2 24 | $-0.13 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $3.2B |
| 总资产 | $5.1B | $3.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALNYRDDT
| Q1 26 | $1.7B | $1.4B | ||
| Q4 25 | $1.7B | $953.6M | ||
| Q3 25 | $1.5B | $911.7M | ||
| Q2 25 | $1.1B | $734.1M | ||
| Q1 25 | $1.0B | $635.7M | ||
| Q4 24 | $966.4M | $562.1M | ||
| Q3 24 | $1.1B | $515.9M | ||
| Q2 24 | $968.5M | $468.0M |
股东权益ALNYRDDT
| Q1 26 | $1.1B | $3.2B | ||
| Q4 25 | $789.2M | $2.9B | ||
| Q3 25 | $233.9M | $2.6B | ||
| Q2 25 | $250.6M | $2.4B | ||
| Q1 25 | $115.4M | $2.2B | ||
| Q4 24 | $67.1M | $2.1B | ||
| Q3 24 | $32.4M | $2.0B | ||
| Q2 24 | $-3.1M | $1.9B |
总资产ALNYRDDT
| Q1 26 | $5.1B | $3.5B | ||
| Q4 25 | $5.0B | $3.2B | ||
| Q3 25 | $4.9B | $2.9B | ||
| Q2 25 | $4.6B | $2.6B | ||
| Q1 25 | $4.2B | $2.4B | ||
| Q4 24 | $4.2B | $2.3B | ||
| Q3 24 | $4.2B | $2.2B | ||
| Q2 24 | $4.0B | $2.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | — | $311.0M |
| 自由现金流率自由现金流/营收 | — | 46.9% |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $868.6M |
8季度趋势，按日历期对齐
经营现金流ALNYRDDT
| Q1 26 | — | — | ||
| Q4 25 | $163.6M | $266.8M | ||
| Q3 25 | $325.1M | $185.2M | ||
| Q2 25 | $153.7M | $111.3M | ||
| Q1 25 | $-118.3M | $127.6M | ||
| Q4 24 | $-94.7M | $90.0M | ||
| Q3 24 | $43.7M | $71.6M | ||
| Q2 24 | $124.2M | $28.4M |
自由现金流ALNYRDDT
| Q1 26 | — | $311.0M | ||
| Q4 25 | $140.3M | $263.6M | ||
| Q3 25 | $313.0M | $183.1M | ||
| Q2 25 | $139.4M | $110.8M | ||
| Q1 25 | $-127.3M | $126.6M | ||
| Q4 24 | $-103.8M | $89.2M | ||
| Q3 24 | $39.5M | $70.3M | ||
| Q2 24 | $116.1M | $27.2M |
自由现金流率ALNYRDDT
| Q1 26 | — | 46.9% | ||
| Q4 25 | 12.8% | 36.3% | ||
| Q3 25 | 25.1% | 31.3% | ||
| Q2 25 | 18.0% | 22.2% | ||
| Q1 25 | -21.4% | 32.3% | ||
| Q4 24 | -17.5% | 20.8% | ||
| Q3 24 | 7.9% | 20.2% | ||
| Q2 24 | 17.6% | 9.7% |
资本支出强度ALNYRDDT
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.4% | ||
| Q3 25 | 1.0% | 0.4% | ||
| Q2 25 | 1.8% | 0.1% | ||
| Q1 25 | 1.5% | 0.2% | ||
| Q4 24 | 1.5% | 0.2% | ||
| Q3 24 | 0.8% | 0.4% | ||
| Q2 24 | 1.2% | 0.4% |
现金转化率ALNYRDDT
| Q1 26 | — | — | ||
| Q4 25 | 0.88× | 1.06× | ||
| Q3 25 | 1.29× | 1.14× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 4.88× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 2.40× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
RDDT
暂无分部数据
